Biogen Pharmachem Industries Ltd

Biogen Pharmachem Industries Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 08 September 2025. However, the analysis and financial metrics discussed below reflect the stock's current position as of 07 August 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Biogen Pharmachem Industries Ltd., a micro-cap non-banking financial company, reported a net profit of ₹0.22 crores in Q1 FY27 (Jun'26), marking a reversal from the previous quarter's loss of ₹0.36 crores. However, this modest turnaround does little to address the company's fundamental challenges, as the stock continues its brutal descent, plummeting 63.75% over the past year and trading 64.20% below its 52-week high of ₹0.81. With a market capitalisation of just ₹32.00 crores and zero institutional backing, the company remains trapped in a bearish technical trend whilst grappling with negligible revenue generation and anaemic return ratios.

Biogen Pharmachem Industries Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 08 Sep 2025, reflecting a significant reassessment of the stock’s outlook. However, the analysis and financial metrics discussed below represent the company’s current position as of 24 July 2026, providing investors with the latest insights into its performance and prospects.

Biogen Pharmachem Industries Ltd’s stock price declined sharply to hit a new 52-week low of Rs.0.27 on 8 July 2026, marking a significant downturn amid broader market weakness and company-specific financial pressures.

Biogen Pharmachem Industries Ltd’s stock price declined sharply to a new 52-week low of Rs.0.29 on 03 Jul 2026, marking a significant downturn amid broader market gains. The stock underperformed its sector and continues to trade below all key moving averages, reflecting ongoing pressures within the company’s financial and operational metrics.

Biogen Pharmachem Industries Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 08 Sep 2025. However, the analysis and financial metrics discussed below reflect the company’s current position as of 03 July 2026, providing investors with an up-to-date perspective on the stock’s fundamentals, valuation, financial trends, and technical outlook.

For the fifth consecutive session, Biogen Pharmachem Industries Ltd has closed lower, slipping to a fresh 52-week low of Rs 0.3 on 30 Jun 2026. This decline extends the stock’s year-long slide to a steep -67.71%, markedly underperforming the Sensex’s modest -8.40% over the same period.

Despite a broadly positive market backdrop with the Sensex gaining 0.17% and several pharma indices hitting new highs, Biogen Pharmachem Industries Ltd has plunged to a fresh 52-week low of Rs.0.31 on 29 Jun 2026, extending its decline amid persistent selling pressure.

Biogen Pharmachem Industries Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 08 Sep 2025. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 18 June 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trend, and technical outlook.

Biogen Pharmachem Industries Ltd’s stock price declined sharply on 03 Jun 2026, hitting a new 52-week low of Rs.0.33, marking a significant downturn in the company’s market performance amid broader sector and market pressures.

A sharp decline of 8.11% today dragged Biogen Pharmachem Industries Ltd to a fresh 52-week low of Rs 0.34, extending its downward trajectory amid persistent selling pressure despite a broadly positive market backdrop.

Biogen Pharmachem Industries Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 08 Sep 2025, reflecting a significant reassessment of the stock’s outlook. However, the analysis and financial metrics discussed below represent the company’s current position as of 21 May 2026, providing investors with the latest insights into its performance and prospects.

Biogen Pharmachem Industries Ltd’s stock price reached a new 52-week low of Rs.0.36 on 21 May 2026, marking a significant decline amid ongoing financial pressures and subdued market performance within the Non Banking Financial Company (NBFC) sector.

Biogen Pharmachem Industries Ltd, a micro-cap player in the Non Banking Financial Company (NBFC) sector, has seen a marked deterioration in its valuation metrics, prompting a downgrade to a Strong Sell rating. With its price-to-earnings (P/E) ratio soaring to 45.45 and price-to-book value (P/BV) plummeting to 0.44, the stock’s price attractiveness has shifted from very expensive to risky, raising concerns among investors amid weak returns and poor profitability indicators.